Mirae Asset Global ETFs Holdings
OVID icon

Mirae Asset Global ETFs Holdings’s Ovid Therapeutics OVID Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-37,012
Closed -$11.5K – 3176
2025
Q1 		$11.5K Buy
37,012
+1,482
+4% +$911 ﹤0.01% 3017
2024
Q4 		$33.2K Buy
35,530
+1,444
+4% +$1.62K ﹤0.01% 2957
2024
Q3 		$40.2K Buy
34,086
+3,173
+10% +$3.31K ﹤0.01% 2962
2024
Q2 		$23.8K Buy
+30,913
New +$86K ﹤0.01% 2904

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's OVID Position: Q2 2025 in Review

Mirae Asset Global ETFs Holdings sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 37,012 shares — an estimated $11.5K sold.

Mirae Asset Global ETFs Holdings first reported a position in OVID in Q2 2024 and held it in 4 quarters. The position peaked at $40.2K in Q3 2024. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • Mirae Asset Global ETFs Holdings reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 37,012 Ovid Therapeutics shares in Q2 2025, an estimated $11.5K.
  • Mirae Asset Global ETFs Holdings first reported a position in Ovid Therapeutics in Q2 2024 and held it in 4 quarters.
  • Mirae Asset Global ETFs Holdings's Ovid Therapeutics position peaked at $40.2K in Q3 2024.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.